Michael Schmohl

Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial

Stephan Glund, Joachim Stangier, Michael Schmohl et al. · The Lancet · 2015 · 317 citations

Thrombosis, Venous Thrombosis, Cardiovascular Disease +8

A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran

Viktoria Moschetti, Stephen H. Norris, Joachim Stangier et al. · Thrombosis and Haemostasis · 2015 · 244 citations

Drug Safety, Translational Medicine, Monoclonal Antibody Fragment +15

Effect of Age and Renal Function on Idarucizumab Pharmacokinetics and Idarucizumab-Mediated Reversal of Dabigatran Anticoagulant Activity in a Randomized, Double-Blind, Crossover Phase Ib Study

Stephan Glund, Joachim Stangier, Joanne van Ryn et al. · Clinical Pharmacokinetics · 2016 · 85 citations · Full text

Idarucizumab, a Specific Antidote for Dabigatran: Immediate, Complete and Sustained Reversal of Dabigatran Induced Anticoagulation in Elderly and Renally Impaired Subjects

Stephan Glund, Joachim Stangier, Michael Schmohl et al. · Blood · 2014 · 70 citations

Abstract 17765: A Specific Antidote for Dabigatran: Immediate, Complete and Sustained Reversal of Dabigatran Induced Anticoagulation in Healthy Male Volunteers

Stephan Glund, Joachim Stangier, Michael Schmohl et al. · Circulation · 2013 · 48 citations

Pharmacotherapy, Thrombosis, Venous Thrombosis +17